SB-505124（Cat No.:I004609）is a selective small molecule inhibitor of the transforming growth factor-beta (TGF-β) type I receptor (ALK5). TGF-β signaling is involved in various biological processes, including cell growth, differentiation, and fibrosis. Dysregulated TGF-β signaling is

SB 505124

SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptor ALK5 and as well as being a selective inhibitor of ALK4 but with less potency. SB-505124 blocks TGF-β-induced apoptosis of FaO cells and

SB-505124 is an inhibitor of activin receptor-like kinase (ALK-5). SB-505124 is demonstrated to suppress the action of transforming growth factor-B (TGF-B) both in vitro and in vivo.

Inhibitor of ALK4, ALK5, and ALK7 receptors. Inhibitor of ALK4, ALK5, and ALK7 receptors.

SB505124 is a selective inhibitor of transforming growth factor-β type I receptor (ALK5, ALK4 and ALK7) with potential anticancer activity. SB505124 selectively inhibits signaling from TGF-β and activin but does not inhibit other ALK family

SB-505124 is a selective inhibitor of TGF-β Receptor type I receptors (ALK4, ALK5, ALK7), with IC50s of 129 nM and 47 nM for ALK4, ALK5, respectively, but it does not inhibit ALK1, 2, 3, or

SB505124 is a selective inhibitor of TGFβR for ALK4, ALK5 with IC50 of 129 nM and 47 nM in cell-free assays, respectively, also inhibits ALK7, but does not inhibit ALK1, 2, 3, or 6.